The abstract is read at the publisher; the summary is JClub's.
In the Sister Study cohort, higher prediagnostic plasma PFOA and PFOS levels are linked to increased ER-negative breast cancer incidence, with HRs up to 1.93.
- Why it matters: PFAS and breast cancer associations have been inconsistent, and hormone receptor–specific evaluation is limited, leaving uncertainty about which PFAS might relate to ER-negative disease.
- What they did: A case-cohort analysis measured 17 PFASs in prediagnostic plasma by liquid chromatography-high-resolution mass spectrometry in 1,609 cases and 2,269 subcohort participants, using sampling-weighted Cox models and hormone receptor–stratified estimates.
- The result: ER-negative tumors showed positive associations for PFOA (HR Q4 v Q1, 1.67; P trend = .09) and PFOS (HR Q4 v Q1, 1.93; P trend = .01), and meta-analysis of seven studies supported ER-negative links for PFOA (RR 1.30) and PFOS (RR 1.20).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.